Don't have Telegram yet? Try it now!
https://www.businessline.global/rhizen-pharmaceuticals-sa-announces-presentation-of-the-interim-results-of-the-phase-i-ii-study-of-tenalisib-rp6530-in-combination-with-romidepsin-in-relapsed-refractory-t-cell-lymphoma-at-american/
Rhizen Pharmaceuticals SA Announces Presentation of the Interim Results of the Phase I/II study of Tenalisib (RP6530) in Combination with Romidepsin in Relapsed/Refractory T-cell Lymphoma at American Society of Hematology (ASH) annual meeting, 2020